ADC Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $16,427 | $18,839 | $23,033 | $16,910 |
Gross Profit | 15,225 | 18,003 | 20,972 | 15,539 |
EBITDA | -27,452 | -41,555 | -25,687 | -18,832 |
EBIT | -27,574 | -42,395 | -26,488 | -19,625 |
Net Income | -40,966 | -56,646 | -38,602 | -30,727 |
Net Change In Cash | 16,427 | 18,839 | 23,033 | 16,910 |
Free Cash Flow | -29,630 | -24,087 | -56,598 | -21,942 |
Cash | 234,738 | 264,560 | 194,701 | 250,867 |
Basic Shares | 136,446 | 113,743 | 107,202 | 105,396 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $70,837 | $69,558 | $209,908 | $33,917 |
Gross Profit | 64,888 | 67,029 | 206,607 | 32,524 |
EBITDA | -102,649 | -145,827 | -107,698 | -230,535 |
EBIT | -105,925 | -149,094 | -110,086 | -233,165 |
Net Income | -157,846 | -240,053 | -157,128 | -230,026 |
Net Change In Cash | 70,837 | 69,558 | 209,908 | 33,917 |
Free Cash Flow | -124,702 | -121,902 | -138,998 | -239,754 |
Cash | 250,867 | 278,598 | 326,441 | 466,544 |
Basic Shares | 97,159 | 81,712 | 78,152 | 76,748 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.19 |
2025-06-30 | -$0.25 |
2025-03-31 | -$0.36 |
